Mariana Barcenas1, Teryn R Suhr2, C Ronald Scott3, Frantisek Turecek1, Michael H Gelb4. 1. Departments of Chemistry, University of Washington, Seattle, WA 98195, United States. 2. MLD Foundation, 21345 Miles Dr., West Linn, OR 97068, United States. 3. Departments of Pediatrics, University of Washington, Seattle WA 98195, United States. 4. Departments of Chemistry, University of Washington, Seattle, WA 98195, United States; Departments of Biochemistry, University of Washington, Seattle, WA 98195, United States. Electronic address: gelb@chem.washington.edu.
Abstract
BACKGROUND: Treatments are being developed for metachromatic leukodystrophy (MLD), suggesting the need for eventual newborn screening. Previous studies have shown that sulfatide molecular species are increased in the urine of MLD patients compared to samples from non-MLD individuals, but there is no data using dried blood spots (DBS), the most common sample available for newborn screening laboratories. METHODS: We used ultra-high performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) to quantify sulfatides in DBS and dried urine spots from 14 MLD patients and 50 non-MLD individuals. RESULTS: Several sulfatide molecular species were increased in dried urine samples from all MLD samples compared to non-MLD samples. Sulfatides, especially low molecular species, were increased in DBS from MLD patients, but the sulfatide levels were relatively low. There was good separation in sulfatide levels between MLD and non-MLD samples when dried urine spots were used, but not with DBS, because DBS from non-MLD individuals have measurable levels of sulfatides. CONCLUSION: Sulfatide accumulation studies in urine, but not in DBS, emerges as the method of choice if newborn screening is to be proposed for MLD.
BACKGROUND: Treatments are being developed for metachromatic leukodystrophy (MLD), suggesting the need for eventual newborn screening. Previous studies have shown that sulfatide molecular species are increased in the urine of MLDpatients compared to samples from non-MLD individuals, but there is no data using dried blood spots (DBS), the most common sample available for newborn screening laboratories. METHODS: We used ultra-high performance liquid chromatography/tandem mass spectrometry (UHPLC/MS/MS) to quantify sulfatides in DBS and dried urine spots from 14 MLDpatients and 50 non-MLD individuals. RESULTS: Several sulfatide molecular species were increased in dried urine samples from all MLD samples compared to non-MLD samples. Sulfatides, especially low molecular species, were increased in DBS from MLDpatients, but the sulfatide levels were relatively low. There was good separation in sulfatide levels between MLD and non-MLD samples when dried urine spots were used, but not with DBS, because DBS from non-MLD individuals have measurable levels of sulfatides. CONCLUSION:Sulfatide accumulation studies in urine, but not in DBS, emerges as the method of choice if newborn screening is to be proposed for MLD.
Authors: Alessandra Biffi; Eugenio Montini; Laura Lorioli; Martina Cesani; Francesca Fumagalli; Tiziana Plati; Cristina Baldoli; Sabata Martino; Andrea Calabria; Sabrina Canale; Fabrizio Benedicenti; Giuliana Vallanti; Luca Biasco; Simone Leo; Nabil Kabbara; Gianluigi Zanetti; William B Rizzo; Nalini A L Mehta; Maria Pia Cicalese; Miriam Casiraghi; Jaap J Boelens; Ubaldo Del Carro; David J Dow; Manfred Schmidt; Andrea Assanelli; Victor Neduva; Clelia Di Serio; Elia Stupka; Jason Gardner; Christof von Kalle; Claudio Bordignon; Fabio Ciceri; Attilio Rovelli; Maria Grazia Roncarolo; Alessandro Aiuti; Maria Sessa; Luigi Naldini Journal: Science Date: 2013-07-11 Impact factor: 47.728
Authors: Zhidan Chen; Stephen L Coy; Evan L Pannkuk; Evagelia C Laiakis; Adam B Hall; Albert J Fornace; Paul Vouros Journal: J Am Soc Mass Spectrom Date: 2016-07-08 Impact factor: 3.109
Authors: Maria Blomqvist; Jan Borén; Henrik Zetterberg; Kaj Blennow; Jan-Eric Månsson; Marcus Ståhlman Journal: J Lipid Res Date: 2017-05-26 Impact factor: 5.922